BCS Paladin, that is incorrect.
Look at the PII 2nd ln NSCLC that was a registration al trial.
So the PI PII PIII is the traditional path for a new drug.
here PPHM has demonstrated safety on more then sufficient patients in CHEM, VIRAL and even in I-O.
Furthermore nobody says PPHM will follow the traditional path. The FDA today has other paths to approval which are much shorter.
Finally as explain several times before PPHM does not depend on Cash, Avid and Bavituximab commercial sales (= needs approval which today it doesn't has) only. In their situation there are plenty of of other early cash opportunities by making the right deals (now that they must have left the go-it-alone attempt scenario) that will KEEP their IP and pipelines unencumbered in the end which is what gives them negotiation leverage.
Market Data 
Markets 
AI
